Champagne or Sham Pain?

You can almost hear the champagne corks popping as Amgen (AMGN) just notched all-time highs and sits comfortably in the portfolios of risk-averse institutions and dividend disciples alike. But in biotech, comfort can be deceptive.

Beneath the surface, a patent cliff is forming, a tax storm is brewing, and the pipeline looks more “under renovation” than “ready for liftoff.” There’s no need to panic, but we do need to pay attention.

The engine of Amgen’s historical performance – blockbuster biologics like Enbrel, Prolia, Xgeva, and Otezla – is starting to sputter.

Enbrel, once a $6 billion workhorse, is now limping along at just over $3 billion. Even with U.S. biosimilar protection until 2029, the global landscape is less forgiving.

And the autoimmune market isn’t what it used to be. New mechanisms like TYK2 and IL-23 inhibition are overtaking TNF inhibitors in both efficacy and enthusiasm.

Prolia and Xgeva, meanwhile, are facing real biosimilar competition, and Otezla’s exclusivity clock is ticking, with Repatha not far behind. Taken together, that’s about a third of Amgen’s revenue staring down near-term erosion.

Now, Amgen isn’t asleep at the wheel. The company’s made bold moves – most notably, the $27.8 billion acquisition of Horizon Therapeutics. The deal brought in three rare disease therapies with high-margin potential, but early returns have been underwhelming.

Tepezza, Uplizna, and Krystexxa all missed analyst estimates last quarter, and softness in volume and inventory raised eyebrows. This could be temporary digestion, or it could be a sign that Amgen overpaid for growth that won’t scale as easily as hoped.

The real swing factor is MariTide, Amgen’s once-monthly entrant into the GLP-1 weight loss arms race. On paper, it checks the right boxes: strong efficacy, less frequent dosing, and a clear market opportunity.

But early whispers of bone density side effects clipped expectations, and peak sales estimates have come down considerably, now landing in the $3 to $5 billion range. It could still be a winner, but it’s unlikely to single-handedly fill the revenue hole left by fading legacy products.

Elsewhere in the pipeline, the outlook is mixed. Several programs are facing fierce competition or struggling with clinical efficacy – examples like Aimovig, olpasiran, and bemarituzumab illustrate just how thin the margin of error is in modern biopharma.

When everyone is chasing the same targets and the market’s saturated with innovation, differentiation is everything. Amgen’s candidates aren’t necessarily weak but they’re not obviously dominant either.

Then there’s the not-so-small matter of the IRS. A $10.7 billion tax dispute tied to Puerto Rican manufacturing profits has been simmering in the background.

With past precedents like Coca-Cola (KO) and Medtronic (MDT) going against the taxpayer, the risk here is material.

Amgen’s already provisioned about $3.9 billion, but a ruling against them could take a chunk out of earnings equivalent to a full fiscal year – and open the door to further claims. While this isn’t the kind of thing you build into your DCF model, it’s the kind of thing that hits like a meteor when it lands.

Financially, Amgen still generates the kind of cash flow that CFOs dream about. But margins are drifting lower, debt has ballooned post-Horizon, and R&D now competes with interest payments and dividends for its slice of the pie.

The capital allocation story is becoming trickier to defend, and the tightrope between rewarding shareholders today and fueling growth for tomorrow is getting thinner. It’s not a crisis (yet), but it might just be the company’s new reality.

So where does this leave us? This isn’t a flashing red light, but it’s no green light either. It’s the kind of moment where holding makes sense – re-evaluating, watching, waiting.

If MariTide delivers, if Horizon’s products catch a tailwind, and if the tax issue resolves favorably, Amgen could regain its stride.

If not, the stock might spend the next few years moving sideways, looking more like a yield vehicle than a growth story.

That’s why, for now, holding steady and watching closely may be the most intelligent move on the board.

Because in biotech – as in champagne – you want to be sure it’s not just bubbles.